Randomization-based nonparametric methods for the analysis of multicentre trials

LaVange, Lisa M.; Durham, Todd A.; Koch, Gary G.
June 2005
Statistical Methods in Medical Research;Jun2005, Vol. 14 Issue 3, p281
Academic Journal
journal article
Multicentre trials offer several advantages over single centre trials in clinical research, including the ability to recruit patients at a faster rate over the course of the study, increased generalizability through the use of a broader patient population, and the ability to shed light on the replication of findings at multiple centres in a single study. A nonparametric approach to the analysis of multicentre trial data provides a convenient way for addressing the role of centres as well as baseline covariables during data analysis. With the use of randomization-based nonparametric methods, the strategy for evaluating the null hypothesis of no treatment effect can be prespecified during study planning without requiring a specific structure for the relationship of response criteria (or endpoints) to centres, covariables, or potential interaction terms. Further, the basis of inference for the application of these methods is the randomization mechanism, and the population to which inference can be directly made is the study population itself. No assumptions about underlying distributions, data structures, likelihood functions, or samples from super populations of inference are required. A three-step approach is proposed for handling centres via randomization-based nonparametric methods. In Step 1, a test of overall treatment effect is carried out using data from all centres simultaneously, without any assumption about treatment by centre interaction. In Step 2, the question of treatment by centre interaction is addressed, usually through the use of parametric multiple regression methods. In cases with suggestion of such interaction, Step 3 is conducted to evaluate different weighting schemes in forming pairwise treatment comparisons averaged across centres to assess the robustness of treatment effects observed in Step 1. An attractive inferential feature of this three-step approach is that the Type I error for the test of treatment effect is controlled by requiring statistical significance at each step to proceed to the next step. Extended Mantel-Haenszel methods with stratification adjustment for centre can be used to provide a nonparametric assessment of treatment effect. When adjustment for other covariates, such as baseline values, is desired, the more recent nonparametric analysis of covariance methods are available. Both methods are easy to use, require no assumptions beyond that of a valid randomization mechanism, and can be applied in a similar manner to dichotomous, ordinal, failure time, or continuous response criteria (endpoints). The methods are illustrated using data from a confirmatory clinical trial of a therapeutic agent for the treatment of dry eye disease.


Related Articles

  • Phase III Failures: What Can Be Done? Beltangady, Mohan // Applied Clinical Trials;Sep2005, Vol. 14 Issue 9, p82 

    Looks at what can be done to prevent failures in Phase III clinical trials. Increasing costs of drug development; Possible reasons for why Phase III trials may fail to confirm what has been learned from Phase II studies; Value of flexible trial designs.

  • Antitumor Efficacy Testing in Rodents. Hollingshead, Melinda G. // JNCI: Journal of the National Cancer Institute;11/5/2008, Vol. 100 Issue 21, p100 

    The preclinical research and human clinical trials necessary for developing anticancer therapeutics are costly. One contributor to these costs is preclinical rodent efficacy studies, which, in addition to the costs associated with conducting them, often guide the selection of agents for clinical...

  • Considerations in the development of circulating tumor cell technology for clinical use. Parkinson, David R.; Dracopoli, Nicholas; Gumbs Petty, Brenda; Compton, Carolyn; Cristofanilli, Massimo; Deisseroth, Albert; Hayes, Daniel F.; Kapke, Gordon; Kumar, Prasanna; Lee, Jerry S. H.; Liu, Minetta C.; McCormack, Robert; Mikulski, Stanislaw; Nagahara, Larry; Pantel, Klaus; Pearson-White, Sonia; Punnoose, Elizabeth A.; Roadcap, Lori T.; Schade, Andrew E.; Scher, Howard I. // Journal of Translational Medicine;2012, Vol. 10 Issue 1, p138 

    This manuscript summarizes current thinking on the value and promise of evolving circulating tumor cell (CTC) technologies for cancer patient diagnosis, prognosis, and response to therapy, as well as accelerating oncologic drug development. Moving forward requires the application of the classic...

  • Post Credit Crunch Opportunities. Varawalla, Nermeen // Applied Clinical Trials;Sep2009, Vol. 18 Issue 9, p70 

    The article discusses the opportunity of emerging countries to help in changing the way clinical trials are performed. It mentions that international sponsors are willing to develop innovative medicines at low prices. It notes that governments of emerging countries are dedicated to attract...

  • Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours. Thomas, Huw D.; Lind, Michael J.; Ford, Judith; Bleehen, Norman; Calvert, A. Hilary; Boddy, Alan V. // Cancer Chemotherapy & Pharmacology;Apr2000, Vol. 45 Issue 4, p284 

    Introduction: Cereport (RMP-7) is a novel bradykinin agonist which is being developed as a modulator of the blood–brain barrier (BBB). In order to investigate the pharmacokinetics of carboplatin in combination with Cereport, we performed pharmacological studies in conjunction with early...

  • Defining Clinical Malaria: The Specificity and Incidence of Endpoints from Active and Passive Surveillance of Children in Rural Kenya. Olotu, Ally; Fegan, Gregory; Williams, Thomas N.; Sasi, Philip; Ogada, Edna; Bauni, Evasius; Wambua, Juliana; Marsh, Kevin; Borrmann, Steffen; Bejon, Philip // PLoS ONE;2010, Vol. 5 Issue 12, p1 

    Background: Febrile malaria is the most common clinical manifestation of P. falciparum infection, and is often the primary endpoint in clinical trials and epidemiological studies. Subjective and objective fevers are both used to define the endpoint, but have not been carefully compared, and the...

  • NEW INSIGHT ON TREATING GLAUCOMA.  // Review of Optometry;3/15/2004 Supplement, Vol. 141, p45A 

    The article presents information on the Early Manifest Glaucoma Trial (EMGT). EMGT was a controlled clinical trial that evaluated the effectiveness of reducing IOP in patients with newly detected, previously untreated, early glaucoma. Results from this landmark study have shed light on managing...

  • Deciphering Anatomic Outcomes: Other Clues to Efficacy. Lim, Jennifer I. // Ophthalmology Times;8/15/2006 Supplement 13, Vol. 31, p8 

    The article discusses the key anatomical outcomes included in 2 phase 3 clinical trials of ranibizumab in the health care industry in the U.S. Two of the phase 3 trials include Classic/Occult Trial of Anti-Vascular Endothelial Growth Factor (VEGF) Antibody RhuFab V2 in the Treatment of...

  • Find the Trial Size that Fits. Harding, Valerie // Drug Discovery & Development;Jun2011, Vol. 14 Issue 6, p26 

    The article focuses on the use of Bayesian methods in clinical trials to provide evidence showing significant therapeutic results and efficacy of the new chemical entity (NCE) in the U.S. It mentions the applicability of the simulations within the Bayesian approach to evaluate whether various...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics